News

Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as ...
Infectious Disease Advisor16d
FDA Approves Moderna’s Next-Generation COVID-19 Vaccine mNexspike
The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.
InvestorsHub on MSN23d
Moderna Shares Climb After FDA Approval of Next-Gen COVID-19 Vaccine
Moderna (NASDAQ:MRNA) saw its stock rise nearly 5% in premarket trading on Monday following the U.S. Food and Drug Administration’s approval of its next-generation COVID-19 vaccine, mNEXSPIKE. The ...
Fox News23d
Greene slams FDA green lighting of Moderna's mNEXSPIKE COVID-19 vaccine | Fox News
Rep. Marjorie Taylor Greene, R-Ga., slammed the U.S. Food and Drug Administration's move to give the green light to Moderna's mNEXSPIKE COVID-19 vaccine. "Not MAHA at all!!!," the congresswoman ...
Hosted on MSN18d
Marjorie Taylor Greene slams FDA green lighting of mNEXSPIKE COVID-19 vaccine: 'Not MAHA at all!!!'
"MNEXSPIKE is approved for use in individuals who have been previously vaccinated with any COVID-19 vaccine and are 65 years of age and older, or 12 years through 64 years of age with at least one ...
News on 623d
What to know about Moderna’s new ‘mNexspike’ COVID-19 vaccine
The FDA has approved a new COVID-19 vaccine developed by Moderna, offering a lower-dose option aimed at older adults and people with underlying health risks. The vaccine, named mNexspike, is part ...
The National Law Review26d
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE - National Law Review
mNEXSPIKE becomes Moderna's third FDA-approved product. CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA ...
US okays Moderna's 'next generation' Covid-19 vaccine
The new vaccine, mNexspike (mRNA-1283), is a step toward next-generation coronavirus vaccines. It’s made in a way that allows for a lower dose, a fifth of the dose of its current COVID-19 vaccine, Spi ...
Top Stock Movers Now: Ford, Cleveland-Cliffs, Moderna, and More
U.S. equities were mixed at midday after China accused the U.S. of violating a trade deal the two countries reached last month.
Monthly Prescribing Reference21d
FDA Approves Moderna’s Next-Generation COVID-19 Vaccine mNexspike
The mNexspike vaccine is supplied as a single-dose prefilled syringe containing 1 dose of 0.2mL. The single 0.2mL dose should be administered at least 3 months after the last dose of COVID-19 vaccine.
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
NEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has ...